Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival-Reference-Cited by-同舟云学术

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival

Published:2008-05 Issue:2 Volume:109 Page:174-181
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Alberts David S.,Marth Christian,Alvarez Ronald D.,Johnson Gary,Bidzinski Mariusz,Kardatzke David R.,Bradford Williamson Z.,Loutit Jeff,Kirn David H.,Clouser Mary C.,Markman Maurie

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference29 articles.

1. Jamal, A, et al. Cancer Statistics 2007. CA Cancer J Clin Jan-Feb 57(1):43–66

2. McGuire. WP. Epithelial ovarian cancer. ASCO 2000 Educational Book 2000;541–6.

3. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study;Ozols;J Clin Oncol,2003

4. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer;du Bois;J Natl Cancer Inst.,2003

5. Biologic and immunologic therapies for ovarian cancer;Berek;J Clin Oncol,2003

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IFNγ-Induced Bcl3, PD-L1 and IL-8 Signaling in Ovarian Cancer: Mechanisms and Clinical Significance;Cancers;2024-07-27

2. Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview;Pharmaceutics;2024-07-24

3. Targeting cytokine and chemokine signaling pathways for cancer therapy;Signal Transduction and Targeted Therapy;2024-07-22

4. Designing monomeric IFNγ: The significance of domain-swapped dimer structure in IFNγ immune responses;Journal of Biological Chemistry;2024-07

5. TGF β1 promotes the polarization of M2-type macrophages and activates PI3K/mTOR signaling pathway by inhibiting ISG20 to sensitize ovarian cancer to cisplatin;International Immunopharmacology;2024-06